D. Boral Capital Reiterates “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX)

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a report issued on Wednesday,Benzinga reports. They presently have a $32.00 price target on the stock.

Other equities analysts also recently issued research reports about the stock. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a report on Monday, September 16th. Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $5.00 to $4.00 in a report on Friday, November 15th. Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a report on Monday, November 11th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Compass Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $11.80.

Compass Therapeutics Trading Up 30.1 %

NASDAQ CMPX opened at $1.86 on Wednesday. The stock has a market capitalization of $255.92 million, a price-to-earnings ratio of -5.03 and a beta of 0.92. The business’s 50 day moving average is $1.57 and its two-hundred day moving average is $1.44. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.68.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. Equities analysts forecast that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp increased its stake in shares of Compass Therapeutics by 12.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock worth $284,000 after purchasing an additional 31,433 shares in the last quarter. Rhumbline Advisers increased its position in Compass Therapeutics by 10.3% during the second quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock worth $132,000 after buying an additional 12,315 shares in the last quarter. Ground Swell Capital LLC purchased a new position in Compass Therapeutics during the second quarter worth $124,000. Renaissance Technologies LLC raised its holdings in shares of Compass Therapeutics by 99.7% in the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after acquiring an additional 70,200 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Compass Therapeutics in the second quarter valued at $41,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.